Contact Us: | Toll Free No: 888 225 2950 | Phone: +1 407 996 9630 | Fax: +1 407 996 9631
Contact Us

News

MEDITE Cancer Diagnostics, Inc. Reports Second Quarter 32% Revenue Increase and Six Months 2016 Results

Orlando, Fl., August 29, 2016 -  MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the “Company”) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its second quarter and six months 2016 results. For the three months ended June 30, 2016,…
Read more

MEDITE Cancer Diagnostics, Inc. Reports $9.9 Million in Revenue and Results for 2015

Orlando, Fl., April 13, 2016 - MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its 2015 financial results. The Company reports $9.9 million in revenue for 2015. It successfully…
Read more

MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) To Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz-Carlton in South Beach on Feb. 22, 2016

Orlando, FL., January 17, 2016 - MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at The…
Read more

MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11th

Orlando, FL., January 7, 2016 - MEDITE Cancer Diagnostics, Inc., (OTC:MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual…
Read more

Medite Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

Orlando, Fl., November 17, 2015 - MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results. The Company reports $2.7 million of revenues and…
Read more

Investment by UNIC Technologies CEO Dr. Zhongxi Zheng for 5.06% of MEDITE Cancer Diagnostics, Inc. Highlights Digital Cancer Diagnostic Strategy

Orlando, FL., September 9, 2015 - MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of immuno-assays and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces an investment by UNIC Medical, Inc.‘s Chairman and UNIC Technologies, Inc.’s CEO, Dr. Zhongxi Zheng, an MD in…
Read more

MEDITE Cancer Diagnostics, Inc. successfully obtained Mexican Tender for 31 Stainers and First Delivery of new Manual Microtome to China

Orlando, FL., August 27, 2015 - MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with…
Read more

MEDITE Cancer Diagnostics, Inc. Reports Second Quarter and Six Month 2015 Results

Orlando, Fl., August 17, 2015 - MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results. The Company reports a comprehensive profit (net of the foreign currency…
Read more

MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor

Orlando, FL, May 14, 2015 – MEDITE Cancer Diagnostics, Inc., (“Company”, OTCQB symbol: “MDIT”) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces change of auditors. On May 13, 2015, upon the recommendation of the Company’s Audit Committee,…
Read more

MEDITE Cancer Diagnostics, Inc. Reports 2014 Year End Results along with Expectations for 2015

Orlando, FL, May 11, 2015 – MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces 2014 results and expectations for 2015. In 2014, MEDITE Enterprise, Inc., with its subsidiaries in Germany, Austria and…
Read more

MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11th

Orlando, FL., January 7, 2016 - MEDITE Cancer Diagnostics, Inc., (OTC:MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual…
Read more